PD-1/PD-L1 inhibitors can inhibit this process and have been approved to treat a wide variety of cancer types including lung cancer, kidney cancer, bladder cancer, and melanoma (22–24). This evidence concerns the gene PDCD1 and urinary bladder carcinoma.